Pfizer Inc. (NYSE:PFE) announced that PROFILE 1014, a phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib), met its primary objective of significantly prolonging progression-free survival (PFS) in previously untreated patients with ALK-positive advanced non-squamous non-small cell lung cancer (NSCLC) when compared to standard platinum-based chemotherapy regimens. Pfizer Inc. (NYSE:PFE) stock performance was 1.13% in last session and finished the day at $32.18. Traded volume was 31.58million shares in the last session and the average volume of the stock remained 26.31million shares. The beta of the stock remained 0.67. Pfizer Inc. (NYSE:PFE) insider ownership is 0.10%.

US drug makers Merck and Co. Inc. and Bristol-Myers Squibb Co. (NYSE:BMY) who had exited India earlier re-entered the market in 2005 with fresh investments. They have also made joint ventures and forged strategic alliances with local firms. Bristol-Myers Squibb Co (NYSE:BMY) rose 3.17 percent to $52.66 Wednesday on volume of 16.14million shares. The intra-day range of the stock was $51.24 to $52.93. Bristol-Myers Squibb Co (NYSE:BMY) has a market capitalization of $87.26billion.

Gilead Sciences Inc. (NASDAQ:GILD) tumbled last week, supposedly on news of patent infringement lawsuits in Europe. The stock actually peaked in February and broke down below its June 2013 trendline a week before the news came out. Gilead Sciences, Inc. (NASDAQ:GILD)’s stock on Mar 26, 2014 reported a decrease of -0.34% to the closing price of $72.78. Its fifty two weeks range is $45.11 -$84.88. The total market capitalization recorded $111.92billion. The overall volume in the last trading session was 15.72million shares. In its share capital, GILD has 1.53billion outstanding shares.

Shares of MannKind Corporation (NASDAQ:MNKD) were the recipient of some unusual options trading activity on Monday. Traders purchased 21,101 call options on the company, AnalystRatings.NET reports. A number of analysts have recently weighed in on MNKD shares. Analysts at Zacks reiterated a “neutral” rating on shares of MannKind Corporation (NASDAQ:MNKD) in a research note on Thursday, February 20th. They now have a $6.25 price target on the stock. Separately, analysts at MLV & Co. reiterated a “buy” rating on shares of MannKind Corporation (NASDAQ:MNKD) in a research note on Thursday, February 20th. On Wednesday, shares of MannKind Corporation (NASDAQ:MNKD) dropped -7.24% to close the day at $5.38. Company monthly performance is recorded as -17.74%. MannKind Corporation (NASDAQ:MNKD) quarterly revenue growth is 4.67%.